Skip to main content

Advertisement

Table 1 (abstract O23). Proportion of responders who maintained optimal control of disease activity* at the end of epoch 4, following treatment with canakinumab (Week 112 analysis)

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

Cohort 150 mg q8w n (%) 150 mg q4w n (%) 300 mg q8w n (%) 300 mg q4w n (%)
crFMF (N=57) 23 (40.4) 20 (35.1) 5 (8.8) 9 (15.8)
TRAPS (N=50) 25 (50.0) 5 (10.0) 9 (18.0) 11 (22.0)
HIDS/MKD (N=64) 14 (21.9) 7 (10.9) 11 (17.2) 32 (50.0)
  1. *Optimal control of disease activity was defined as median of no or 1 flare, and no uptitration